 Webcast and Conference Call to Be Held Wednesday, February 24, 2021 at 8:30 a.m. EST WALTHAM, Mass., Feb. 11, 2021 GLOBE NEWSWIRE -- Repligen Corporation NASDAQ:RGEN today announced that the Company will report its fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2020. The conference call will be accessible by dialing toll-free 844 274-3999 for domestic callers and 412 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations section of the Companys website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are 877 344-7529 for callers in the U.S., 855 669-9658 for callers in Canada and 412 317-0088 for international callers. Replay listeners must provide the passcode 10151931. About Repligen Corporation Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase efficiencies in the process of manufacturing biological drugs. Our primary customers are biopharmaceutical drug developers and contract development and manufacturing organizations CDMOs worldwide. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located in the U.S. California, Massachusetts, New Jersey and New York, and outside of the U.S. we have sites in Estonia, Germany, Ireland, the Netherlands and Sweden. This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like believe, expect, may, will, should, seek, or could and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law. Repligen Contact: Sondra S. NewmanGlobal Head of Investor Relations781 